---
figid: PMC3958497__ijwh-6-289Fig1
figtitle: 'Inhibition of angiogenic pathways: targeting multiple angiogenic ligands
  and cell membrane receptors.Notes: Tumor and host endothelial cells release angiogenic
  ligands that interact in an autocrine and paracrine fashion'
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
- Danio rerio
pmcid: PMC3958497
filename: ijwh-6-289Fig1.jpg
figlink: /pmc/articles/PMC3958497/figure/f1-ijwh-6-289/
number: F1
caption: 'Inhibition of angiogenic pathways: targeting multiple angiogenic ligands
  and cell membrane receptors.Notes: Tumor and host endothelial cells release angiogenic
  ligands that interact in an autocrine and paracrine fashion. Bevacizumab targets
  the VEGF ligand and inhibits VEGF-induction of VEGF receptors. Trebananib binds
  Ang1 and Ang2 ligands, inhibiting binding to the TIE receptor thus preventing activation
  of the angiopoietin pathway. TKI target and inhibit the intracellular component
  of multiple cell membrane tyrosine kinase receptors (PDGF, VEGF, and FGF receptors).Abbreviations:
  PDGF, platelet derived growth factor; VEGF, vascular endothelial growth factor;
  FGF, fibroblast growth factor; Ang1, angiopoietin-1; Ang2, angiopoietin-2; TIE,
  tyrosine kinase with immunoglobulin-like and EGF-like domains 1; TKI, tyrosine kinase
  inhibitors.'
papertitle: Profile of pazopanib and its potential in the treatment of epithelial
  ovarian cancer.
reftext: Brittany A Davidson, et al. Int J Womens Health. 2014;6:289-300.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9608706
figid_alias: PMC3958497__F1
figtype: Figure
redirect_from: /figures/PMC3958497__F1
ndex: 9d02e551-deb9-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3958497__ijwh-6-289Fig1.html
  '@type': Dataset
  description: 'Inhibition of angiogenic pathways: targeting multiple angiogenic ligands
    and cell membrane receptors.Notes: Tumor and host endothelial cells release angiogenic
    ligands that interact in an autocrine and paracrine fashion. Bevacizumab targets
    the VEGF ligand and inhibits VEGF-induction of VEGF receptors. Trebananib binds
    Ang1 and Ang2 ligands, inhibiting binding to the TIE receptor thus preventing
    activation of the angiopoietin pathway. TKI target and inhibit the intracellular
    component of multiple cell membrane tyrosine kinase receptors (PDGF, VEGF, and
    FGF receptors).Abbreviations: PDGF, platelet derived growth factor; VEGF, vascular
    endothelial growth factor; FGF, fibroblast growth factor; Ang1, angiopoietin-1;
    Ang2, angiopoietin-2; TIE, tyrosine kinase with immunoglobulin-like and EGF-like
    domains 1; TKI, tyrosine kinase inhibitors.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - bnl
  - Tie
  - tub
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - ANGPT1
  - TM7SF2
  - ANGPT2
  - VPS51
  - TIE1
  - TUBE1
  - vegfaa
  - angpt1
  - angpt2b
  - kita
  - ngfra
---
